![James P. Brady](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
James P. Brady
Ufficiale delle Risorse Umane presso SPERO THERAPEUTICS, INC.
Posizioni attive di James P. Brady
Società | Posizione | Inizio | Fine |
---|---|---|---|
SPERO THERAPEUTICS, INC. | Ufficiale delle Risorse Umane | - | - |
Storia della carriera di James P. Brady
Precedenti posizioni note di James P. Brady
Società | Posizione | Inizio | Fine |
---|---|---|---|
UNIQURE N.V. | Ufficiale delle Risorse Umane | 01/08/2020 | 01/09/2021 |
Intarcia Therapeutics, Inc.
![]() Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Ufficiale delle Risorse Umane | 01/04/2015 | 01/08/2020 |
Formazione di James P. Brady
Marietta College | Undergraduate Degree |
Harvard University | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Paesi Bassi | 2 |
Posizioni
Human Resources Officer | 3 |
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
UNIQURE N.V. | Health Technology |
SPERO THERAPEUTICS, INC. | Health Technology |
Aziende private | 1 |
---|---|
Intarcia Therapeutics, Inc.
![]() Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- James P. Brady
- Esperienza